Neuropathic Pain - A Plethora of Patient Segmentation and Product Differentiation Opportunities

Questions: Discounts, Updates etc.

Price: $15,200.00

Publication Date: 2006-07-27

Order Online Now

People that purchased this report also purchased:

Contact LeadDiscovery

  • If you have questions about this report
  • To find out if you qualify for a discount
  • Want a more up to date version
  • Can't find a report that meets your needs
Search all reports

Keywords:

Boolean terms AND, OR, NOT can be used. Phrases should be entered within quotes. For wildcards use an *

Neurontin (gabapentin) has finally been knocked off the top spot as a result of fierce generic incursion. However, Pfizer's follow-on Lyrica (pregabalin), Lilly's Cymbalta (duloxetine) and Endo/Elan's Lidoderm (lidocaine patch 5%) are re-establishing market growth and laying the groundwork for new entrants.


Scope

  • Detailed analysis of key brands, with sales and volume forecasts to 2014 for the neuropathic pain indication alone
  • Assessment of current and future opportunities and threats in the neuropathic pain market across the seven major pharmaceutical markets
  • Consideration of key events that may affect revenues in each of the seven major pharmaceutical markets are applied and discussed
  • Lifecycle management case studies show how previously successful strategies should be applied in today's market


    • Report Highlights
    After a brief slump in 2005, the neuropathic pain market is forecast to grow to $5.5 billion by 2015, led by Lyrica and Cymbalta. Pfizer's commitment to neuropathic pain and Lilly's targeted approach are both effective strategies that can be utilized by all new entrants.

    The presence of generic gabapentin has introduced strong cost competition in the market. Setting a competitive price point for a new product is vital as healthcare payers continue to push for lower drug prices and generic prescribing although innovation is rewarded with a premium price and a high level of reimbursement in most countries.

    The current concerns surrounding the use of NSAIDs and opioids will be beneficial to neuropathic pain drug companies as physicians seek alternative analgesics for their patients. However, if they are to realize the full potential of the market, companies need to focus on expanding the patient potential by supporting physician education programs.


    Reasons to Purchase

  • Quantify the future size of the neuropathic pain market in each of the seven major markets
  • Understand key product differentiating factors that provide commercial advantages over existing therapies
  • Compare market penetration and brand positioning strategies to those successfully employed by Pfizer, Endo, and Eli Lilly

    • Table of Contents

    Other users found this report page using the following search terms: neuropathic pain lyrica pain lidoderm neuropathic fibromyalgia cymbalta gabapentin uk approval vs

    If you can't find a report that meets your needs contact LeadDiscovery. We are one of the few report providers with extensive drug development experience and we frequently use this knowledge to help clients source the most appropriate reports or produce reports for them from scratch.